BLUETTI to Release AC180, Making Another Breakthrough in Portable Power Station Area
21.4.2023 13:16:00 EEST | Business Wire | Press release
Spring camping has gradually become popular in recent years, providing a precious chance for people to get rid of the hustle and bustle of urban life and have close contact with nature. However, most of their trips experienced mobile power shortages out there.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230421005196/en/
(Photo: Business Wire)
BLUETTI, a market leader in the energy storage industry, is about to unveil a brand-new model. As a successor of the previous portable stations such as EB150 and EB240, AC180 is designed with a bunch of improvements that kit it up a notch, making it a well-deserved portable power station for emergency backup, sudden blackouts, excursions, and more.
Explore Outdoors with Great Capacity
To help elevate the off-grid lifestyle, BLUETTI equips AC180 with a 1800W constant output power and 1.152Wh capacity, covering almost all power demands of essentials at home or in the wild. Furthermore, AC 180 also comes with a Power Lifting Mode of 2.700W output to effortlessly run high-powered devices like kettles, hair dryers, microwaves, etc.
Besides, AC180 is updated with a 1,7-inch LCD display and bigger font size to make the power consumption and troubleshooting status more visualized and clearly.
Travel with Grab-and-go Power
Pack lighter, travel further. In view of portability, AC180 is ultra compact for effortless transportation as it measures 340mmｘ247mmｘ317mm (H x W x H) and weighs only 35kg. It does not occupy too much space of the truck on the way to the next campsite.
Recharge with High Speed
For outdoor enthusiasts looking for backup power for their camping or RV trips on the road, AC180 is sure to exceed their expectations. Even exploring off the beaten track far from the main grid, the reliable power source is always on call as AC180 supports up to 1.440W Turbo Charging, 0-80% SOC only takes about 45mins! Get it charged before packing up for the getaway, a large amount of power is ready to hit the road when you are.
Live with Uninterrupted Power Supply
Given the UPS system, there’s no need to worry about losing data or hardware damage in the event of a power outage since AC180 can automatically detect the blackout the moment it occurs and seamlessly switch over in 20ms that no one can even be aware of.
Constant Power with Peace of Mind
Keeping high security and longevity in mind, BLUETTI adopts safe and durable LiFePO4 battery cells and guarantees a worry-free warranty for as long as 5 years, which really sets it apart from most competitors throughout the market.
Remotely monitoring AC180 in real time is a no-brainer thanks to the intelligent BLUETTI APP. Now setting up working modes, checking the system conditions, and OTA updates can be done solely with fingertips.
“We’re dedicated to more innovations that’s a right fit for the increasing market demand. Our R&D team once envisioned a power station integrated with portability, capability, and cost performance, and now we’ve made it come true. AC180 has everything users could possibly need without costing an arm and a leg,” said James Ray, the marketing director of BLUETTI.
Availability
Though the debut price is not finally decided yet, it’s believed to be the most affordable power station that worth the wait.
About BLUETTI
From the very beginning, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for our homes and our world. That's why BLUETTI makes its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online at https://www.bluettipower.eu/ or follow BLUETTI on:
YouTube: https://www.youtube.com/c/bluettiofficial
Facebook: https://www.facebook.com/bluettipower.eu/
Twitter: https://twitter.com/bluetti_inc
Instagram: https://www.instagram.com/bluetti_europe/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005196/en/
Contact information
jacinda@bluetti.com
130 4085 7737
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 14:20:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 14:15:00 EEST | Press release
Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined by much of the institutional investment community. Xsolla's presence at SuperReturn International reflects a broader moment: the convergence of a mu
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom